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PStatins and Toxicity
Effect of the Magnitude of Lipid Lowering on Risk of
Elevated Liver Enzymes, Rhabdomyolysis, and Cancer
Insights From Large Randomized Statin Trials
Alawi A. Alsheikh-Ali, MD, Prasad V. Maddukuri, MD, Hui Han, MD, Richard H. Karas, MD, PHD
Boston, Massachusetts
Objectives We sought to assess the relationship between the magnitude of low-density lipoprotein cholesterol (LDL-C) low-
ering and rates of elevated liver enzymes, rhabdomyolysis, and cancer.
Background Although it is often assumed that statin-associated adverse events are proportional to LDL-C reduction, that as-
sumption has not been validated.
Methods Adverse events reported in large prospective randomized statin trials were evaluated. The relationship between
LDL-C reduction and rates of elevated liver enzymes, rhabdomyolysis, and cancer per 100,000 person-years was
assessed using weighted univariate regression.
Results In 23 statin treatment arms with 309,506 person-years of follow-up, there was no significant relationship be-
tween percent LDL-C lowering and rates of elevated liver enzymes (R2 0.001, p  0.91) or rhabdomyolysis
(R2  0.05, p  0.16). Similar results were obtained when absolute LDL-C reduction or achieved LDL-C levels
were considered. In contrast, for any 10% LDL-C reduction, rates of elevated liver enzymes increased signifi-
cantly with higher statin doses. Additional analyses demonstrated a significant inverse association between can-
cer incidence and achieved LDL-C levels (R2  0.43, p  0.009), whereas no such association was demon-
strated with percent LDL-C reduction (R2  0.09, p  0.92) or absolute LDL-C reduction (R2  0.05, p  0.23).
Conclusions Risk of statin-associated elevated liver enzymes or rhabdomyolysis is not related to the magnitude of LDL-C low-
ering. However, the risk of cancer is significantly associated with lower achieved LDL-C levels. These findings
suggest that drug- and dose-specific effects are more important determinants of liver and muscle toxicity than
magnitude of LDL-C lowering. Furthermore, the cardiovascular benefits of low achieved levels of LDL-C may in
part be offset by an increased risk of cancer. (J Am Coll Cardiol 2007;50:409–18) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.073i
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Strategies aimed at lowering low-density li-
poprotein cholesterol (LDL-C) remain a pri-
mary approach for cardiovascular risk reduc-
tion. Of the currently available lipid-altering
drugs, hydroxyl methyl glutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) are
he most effective in LDL-C lowering, and their efficacy in
mproving cardiovascular morbidity and mortality is sup-
orted by a large body of evidence. Recent data from
arge-scale statin trials have demonstrated that more inten-
ive LDL-C lowering, beyond standard goals, offers signif-
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he American Heart Association during the period when this work was performed.
Manuscript received February 14, 2007; accepted February 21, 2007.cant incremental cardiovascular risk reduction (1–3). Rel-
vant to this era of “lower is better” in lipid management are
ontroversial concerns regarding the safety of intensive
DL-C lowering.
See pages 419 and 421
Such concerns are compounded by observations linking
he most potent statins to higher rates of reported adverse
vents, including elevated liver enzymes and rhabdomyolysis
4–6). However, whether the magnitude of LDL-C low-
ring per se is related to the risk of statin-associated adverse
vents is uncertain. The nature of such a relationship, if one
ndeed exists, is pertinent to recent national guidelines
dvocating more intensive LDL-C goals as a viable clinical
trategy in very high-risk patients, and the use of higher
tatin doses required to achieve LDL-C reductions of 30%
o 40% (3). Also relevant to the increasing emphasis on
ggressively lowering LDL-C for cardiovascular protection
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LDL-C Lowering and Risk of Statin Toxicity July 31, 2007:409–18are earlier concerns associating
lower cholesterol levels with an
increased incidence of cancer.
Hence, the present analysis ex-
amines the relationship between
the degree of LDL-C lowering
and the risk of abnormal liver
enzymes and rhabdomyolysis in
arge randomized statin trials. In secondary analyses, poten-
ial associations between LDL-C lowering and the risk of
ancer are also examined.
ethods
MEDLINE search was conducted to identify prospective
andomized controlled statin trials published up to Novem-
er 2005. To ensure adequate exposure and optimize the
ield of reported adverse events, only trials with exposures of
t least 1,000 person-years of follow-up were evaluated. The
ollowing variables were extracted from the published
anuscripts: statin used and dose, number of patients in the
tatin-treatment arm, duration of follow-up, baseline and
chieved LDL-C levels, and number of patients experienc-
ng elevated liver enzymes, rhabdomyolysis, or cancer. Cases
f elevated liver enzymes or rhabdomyolysis were identified
sing the specific criteria for each trial. Rates of elevated
iver enzymes, rhabdomyolysis, and cancer per 100,000
erson-years were calculated.
DL-C lowering and risk of elevated liver enzymes and
habdomyolysis. The primary objective of the current anal-
sis was to assess the relationship between percent LDL-C
eduction and rates of elevated liver enzymes and rhabdo-
yolysis. Additional analyses were performed to assess the
elationship between absolute LDL-C reduction or
chieved LDL-C levels, and the observed rates of elevated
iver enzymes and rhabdomyolysis. To assess the relation-
hip between the statin dose and rates of adverse events after
ontrolling for the magnitude of LDL-C lowering, we
alculated the rates of elevated liver enzymes associated with
ach statin for every 10% reduction in LDL-C. Rates of
levated liver enzymes per 100,000 person-years for each
0% reduction in LDL-C were compared across the fol-
owing categories of statin doses: low dose (lovastatin 20
g, simvastatin 20 mg, and atorvastatin 10 mg), interme-
iate dose (lovastatin 40 mg, simvastatin 40 mg, and
ravastatin 40 mg), and high dose (lovastatin 80 mg,
imvastatin 80 mg, fluvastatin 80 mg, and atorvastatin 80
g). A similar analysis also was performed for individual
tatins across the various doses used in the trials. Because
uch an analysis requires a range of doses to be examined,
nly statins for which different doses were used in several
rials could be assessed individually (lovastatin, simvastatin,
nd atorvastatin). Furthermore, because of the small num-
er of rhabdomyolysis cases across the various statin doses,
he effect of varying statin dose on rates of rhabdomyolysis
Abbreviations
and Acronyms
HMG-CoA  hydroxyl
methyl glutaryl coenzyme A
LDL-C  low-density
lipoprotein cholesterolould not be reliably evaluated. mDL-C lowering and cancer. Similarly, we assessed the
elationship between percent LDL-C reduction and rates of
ewly diagnosed cancer in the statin treatment arms. Ad-
itional analyses were performed to assess the relationship
etween absolute LDL-C reduction or achieved LDL-C
evels, and the observed rates of cancer. To assess the
elationship between statin dose and rates of newly diag-
osed cancer, a dose effect analysis similar to the one
escribed previously for risk of elevated liver enzymes was
erformed across the following categories of statin doses:
ow dose, intermediate dose, and high dose.
tatistical methods. Relationships between the magnitude
f LDL-C lowering and rates of elevated liver enzymes,
habdomyolysis, and cancer were assessed using univariate
egression models. To control for variability in trial size, all
egression analyses were weighted by each trial’s statin arm
ample size. To assess for differences in elevated liver
nzymes among the various statin dose categories, the
hi-square test with appropriate degrees of freedom was
sed. A p value of 0.05 was considered statistically
ignificant. SigmaStat version 3.1 (Systat Software, Inc.,
oint Richmond, California) was used for statistical
nalyses.
esults
total of 23 statin treatment arms were identified with
5,317 statin-allocated patients and cumulative follow-up of
09,506 person-years. Several statins at varying doses were
sed across the trials with a wide range of baseline (106 to
92 mg/dl) and achieved (62 to 142 mg/dl) LDL-C levels
Table 1) (1,2,7–20).
rimary analysis: LDL-C lowering and risk of elevated
iver enzymes and rhabdomyolysis. Of all the statin treat-
ent arms examined (n  23), the number of patients with
levated liver enzymes or rhabdomyolysis could be deter-
ined in 22 and 21 arms, respectively. There was no
ignificant relationship between percent LDL-C lowering
nd rates of elevated liver enzymes (R2 0.001, p  0.91)
Fig. 1). Similar findings were obtained when absolute
DL-C reduction or achieved LDL-C values were exam-
ned (R2  0.07, p  0.12, and R2 0.001, p  0.89,
espectively, data not shown). Likewise, there was no
ignificant relationship between % LDL-C lowering and
ates of rhabdomyolysis (R2  0.05, p  0.16) (Fig. 2).
imilar findings were obtained when absolute LDL-C
eduction or achieved LDL-C values were examined (R2
0.001, p  0.62, and R2  0.07, p  0.14, respectively,
ata not shown). To exclude the possibility that the analysis
f LDL-C lowering versus risk of rhabdomyolysis was
ominated by one trial with a high rate of rhabdomyolysis
simvastatin 80 mg arm of the A to Z trial), a repeat analysis
as conducted without that arm, yielding similar findings of
ack of a significant relationship between rates of rhabdo-
yolysis and percent LDL-C reduction (R2  0.01, p 
0
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July 31, 2007:409–18 LDL-C Lowering and Risk of Statin Toxicity.36), absolute LDL-C reduction (R20.001, p 0.53), or
chieved LDL-C level (R2  0.12, p  0.26).
ffect of statin dose on risk of elevated liver enzymes. There
as a positive and graded relationship between rates of
levated liver enzymes per 100,000 person-years and statin
haracteristics of Large Prospective Randomized Controlled Statin
Table 1 Characteristics of Large Prospective Randomized Cont
Study Arm (Ref. No.) Year Statin Dose*
EXCEL (7) 1991 Lovastatin 20
EXCEL (7) 1991 Lovastatin 20 BID
EXCEL (7) 1991 Lovastatin 40
EXCEL (7) 1991 Lovastatin 80
4S (8) 1994 Simvastatin 20–40
WOSCOPS (9) 1995 Pravastatin 40
CARE (10) 1996 Pravastatin 40
AFCAPS/TexCAPS (11) 1998 Lovastatin 20–40
LIPID (12) 1998 Pravastatin 40
ALLHAT-LLT (13) 2002 Pravastatin 40
LIPS (14) 2002 Fluvastatin 80
HPS (15) 2002 Simvastatin 40
PROSPER (16) 2002 Pravastatin 40
ASCOT-LLA (17) 2003 Atorvastatin 10
A to Z (18) 2004 Simvastatin 20
A to Z (18) 2004 Simvastatin 80
CARDS (19) 2004 Atorvastatin 10
PROVE IT-TIMI 22 (1) 2004 Pravastatin 40
PROVE IT-TIMI 22 (1) 2004 Atorvastatin 80
TNT (2) 2005 Atorvastatin 10
TNT (2) 2005 Atorvastatin 80
IDEAL (20) 2005 Simvastatin 20
IDEAL (20) 2005 Atorvastatin 80
Target dose in milligrams per day, unless otherwise specified. †Mean age not reported in origina
AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT
nglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; A to Z Phase Z of the A to Z trial;
vents Trial; EXCEL Expanded Clinical Evaluation of Lovastatin study; 4S Scandinavian Simvas
ggressive Lipid Lowering study; LIPID  The Long-Term Intervention with Pravastatin in Ischemic
not reported; PROSPER Prospective Study of Pravastatin in the Elderly at Risk; PROVE IT-TIMI
2 study; TNT  Treating to New Targets study; WOSCOP  West of Scotland Coronary Preventio
Figure 1 Relationship Between Rates of Elevated
Liver Enzymes and % LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treat-
ment arms (i.e., number of patients in each arm). LDL-C  low-density lipopro-
tein cholesterol.ose, with a significantly higher rate of elevated liver
nzymes in the high-dose statin category compared with the
ntermediate-dose category, which in turn was significantly
igher than the low-dose statin category (271 vs. 195 vs.
14 per 100,000 person-years for each 10% reduction in
s Included in the Present Analysis
Statin Trials Included in the Present Analysis
n Mean Follow-Up, yrs Male, % Mean Age, yrs
1,642 0.9 59 56
1,646 0.9 59 56
1,645 0.9 59 56
1,649 0.9 59 56
2,221 5.4 82 58
3,302 4.9 100 55
2,081 5 86 59
3,304 5.2 85 58
4,512 6.1 83 62
5,170 4.8 51 66
844 3.9 84 60
0,269 5 75 NR†
2,888 3.2 48 75
5,168 3.3 81 63
2,232 2.0 75 61
2,265 2.0 76 61
1,428 3.9 68 62
2,063 2 78 58
2,099 2 78 58
5,006 4.9 81 61
4,995 4.9 81 61
4,449 4.8 81 62
4,439 4.8 81 62
script, but 48% of patients allocated to simvastatin were 65 years old.
e Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA 
wice daily; CARDS Collaborative Atorvastatin Diabetes Study; CARE Cholesterol and Recurrent
urvival Study; HPS Heart Protection Study; IDEAL Incremental Decrease in Endpoints through
study; LIPS  Lescol Intervention Prevention Study; n  number of statin allocated patients; NR
ravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction
.
Figure 2 Relationship Between Rates of
Rhabdomyolysis and % LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treat-
ment arms (i.e., number of patients in each arm). LDL-C  low-density lipopro-
tein cholesterol.Trial
rolled
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LDL-C Lowering and Risk of Statin Toxicity July 31, 2007:409–18DL-C, p  0.001 for all pair-wise comparisons) (Fig. 3).
similar pattern of higher rates of elevated liver enzymes
ith higher statin doses was also observed when individual
tatins were examined. For each 10% reduction in LDL-C,
he rate of elevated liver enzymes per 100,000 person-years
ith high-dose lovastatin was 2.5 times higher compared
ith low-dose lovastatin (p  0.001) (Fig. 4) and signifi-
antly higher than intermediate-dose lovastatin (p  0.001)
Fig. 4). Likewise, the rate of elevated liver enzymes with
igher doses of simvastatin (80 and 40 mg) was 1.6 times
reater compared with low-dose simvastatin (p  0.006)
Fig. 5). Similarly, the rate of elevated liver enzymes with
Figure 3 Rate of Elevated Liver
Enzymes by Statin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduc-
tion in low-density lipoprotein cholesterol (LDL-C) for the following statin dose
categories: low dose (lovastatin 20 mg, simvastatin 20 mg, and atorvastatin
10 mg), intermediate dose (lovastatin 40 mg, simvastatin 40 mg, and prava-
statin 40 mg), and high dose (lovastatin 80 mg, simvastatin 80 mg, fluvastatin
80 mg, and atorvastatin 80 mg).
Figure 4 Rate of Elevated Liver
Enzymes by Lovastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10%
reduction in low-density lipoprotein cholesterol (LDL-C) for low-dose (20 mg),
intermediate-dose (40 mg), and high-dose (80 mg) lovastatin.tigh-dose atorvastatin was 4.0 times greater compared with
ow-dose atorvastatin (p  0.001) (Fig. 6). There were
nsufficient data to examine intermediate doses of
torvastatin.
econdary analysis: LDL-C lowering and risk of cancer. Of
ll the statin treatment arms examined (n 23), the number
f patients with newly diagnosed cancer during follow-up
ould be determined in 13 arms. Detailed description of
hese statin arms is shown in Table 2. There was no
ignificant relationship between percent LDL-C lowering
nd rates of cancer (R2 0.09, p 0.92) (Fig. 7). Similarly,
here was no significant relationship between absolute
DL-C lowering and rates of cancer (R2  0.05, p  0.23)
Fig. 8). In contrast, there was a highly significant inverse
elationship between achieved LDL-C levels and rates of
ewly diagnosed cancer (R2  0.43, p  0.009) (Fig. 9).
he rates of incident cancer across the 3 statin dose
ategories (for each 10 % reduction in LDL-C) ranged from
08 to 498 per 100,000 person-years (Fig. 10). Although
he difference between the high-dose and the low/
ntermediate-dose categories was statistically significant, the
agnitude of this difference was relatively small (low dose
98 vs. intermediate dose 490 vs. high dose 408 per 100,000
erson-years for each 10% reduction in LDL-C, p  0.823
or low vs. intermediate, and p  0.003 and 0.007 for high
s. low and intermediate, respectively) (Fig. 10).
iscussion
DL-C lowering and risk of elevated liver enzymes and
habdomyolysis. Recent reports suggesting an increased
isk of adverse events with more potent statins have raised
nterest in the relationship between statin potency (as
eflected by degree of LDL-C lowering) and statin toxicity.
n the present analysis of large-scale randomized statin
Figure 5 Rate of Elevated Liver
Enzymes by Simvastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10%
reduction in low-density lipoprotein cholesterol (LDL-C) for low-dose (20 mg),
intermediate-dose (40 mg), and high-dose (80 mg) simvastatin.rials, we found no correlation between the magnitude of
L
l
d
r
l
L
a
l
s
m
a
n
t
t
Z
7
s
1
L
s
h
i
L
s
r
a
i
s
i
t
L
c
t
a
c
i
l
d
r
i
L
i
r
c
i
r
i
T
f
2
a
o
s
t
p
L
t
o
r
u
t
m
r
t
a
a
a
n
t
a
t
i
t
b
s
s
a
i
r
p
b
L
c
t
s
n
413JACC Vol. 50, No. 5, 2007 Alsheikh-Ali et al.
July 31, 2007:409–18 LDL-C Lowering and Risk of Statin ToxicityDL-C lowering and rates of statin-associated elevated
iver enzymes or rhabdomyolysis. This was true whether the
egree of LDL-C lowering was assessed as percent LDL-C
eduction, absolute LDL-C reduction, or achieved LDL-C
evel. The present findings do not support the notion that
DL-C lowering per se is related to risk of liver or muscle
dverse events. Instead, we observed that rates of elevated
iver enzymes were significantly associated with the dose of
tatin used, even after controlling for the corresponding
agnitude of LDL-C reduction, whether all statins are
ssessed as a group, or individually.
Furthermore, although a similar dose effect analysis could
ot be reliably preformed for rhabdomyolysis risk because of
he small number of reported cases, it is worth noting that
he one trial with high-dose simvastatin (80 mg in the A to
trial) had a rate of rhabdomyolysis that was more than
-fold higher than the reported rate in intermediate-dose
imvastatin trials (67 vs. 9 cases of rhabdomyolysis per
00,000 person-years). However, the incremental percent
DL-C reduction with high- versus intermediate-dose
imvastatin was only 9%, which is consistent with the
ypothesis that the risk of rhabdomyolysis was driven by the
ncrease in dose and not the incremental reduction in
DL-C. It is unclear whether this observation is unique to
imvastatin only or whether it could be extrapolated to the
isk of muscle toxicity with other statins, especially because
n increased risk of rhabdomyolysis has not been observed
n clinical trials of other high-dose statins such as atorva-
tatin, which has been extensively studied.
The present observations are relevant to the use of statins
n clinical practice in light of recent evidence demonstrating
hat the use of high-dose statins to achieve more intensive
DL-C lowering results in greater reduction in cardiovas-
ular risk (1–3). It is difficult from these trials to differentiate
he influence of LDL-C lowering per se from that of drug
nd dose used. In other words, was the observed benefit
onferred by the higher statin dose, or was the benefit
nstead derived from the greater magnitude of LDL-C
owering achieved by the higher dose of the statin?
Relevant to this question are recent studies examining the
eterminants of benefit with lipid-lowering therapy. A
ecent meta-analysis suggested that the absolute benefit seen
n statin trials related primarily to the absolute reduction in
DL-C (21). Furthermore, in a recent analysis of random-
zed controlled trials using various methods for LDL-C
eduction, the relationship between LDL-C lowering and
ardiovascular risk in statin trials was similar to that found
n non-statin trials, supporting the concept that reduction in
isk is driven by reduction in LDL-C (22). Further insight
s provided by subgroup analyses from the PROVE IT–
IMI-22 (Pravastatin or Atorvastatin Evaluation and In-
ection Therapy–Thrombolysis In Myocardial Infarction-
2) trial, suggesting that once LDL-C target levels were
chieved, the specific statin used did not appear to impact
utcomes (23,24). Similar findings were reported in a recent
tudy comparing the effects of aggressive versus conven-ional lipid lowering where positive changes in vessel wall
arameters were primarily related to the magnitude of
DL-C reduction rather than the statin dose (25). Taken
ogether, these reports suggest that the primary determinant
f benefit with statin use is the magnitude of LDL-C
eduction and not the particular statin or dose used.
The findings from the present study complement our
nderstanding of the effects of statins by demonstrating
hat, unlike the case with statin benefit, the primary deter-
inant of statin toxicity is not the magnitude of LDL-C
eduction, but rather the statin dose used. Hence, based on
he suggestion that a higher dose per se does not confer
dditional benefit after controlling for LDL-C reduction,
nd the present observation that a higher dose of statin is
ssociated with increased risk of toxicity, it may be prudent
ot to use a statin dose beyond what is required to achieve
he LDL-C target. It should be noted, however, that this
pproach is not supported by direct evidence from clinical
rials. In the absence of such evidence, we are left with
ndirect ways of differentiating the effect of the statin and
he dose from that of the resulting reduction in LDL-C on
oth benefit and toxicity.
The present analysis may also be relevant to our under-
tanding of the mechanisms of statin toxicity, particularly
tatin-induced myopathy. Proposed theories for the mech-
nism of statin-induced myopathy invoke either structural
nstability of skeletal muscle cell membranes as a result of
educed cholesterol content, or inhibition of biosynthetic
athways such as ones that activate guanosine triphosphate-
inding regulatory proteins (5). To the extent that serum
DL-C levels correlate with cell membrane cholesterol
ontent, the lack of an association between LDL-C reduc-
ion and risk of rhabdomyolysis observed in this analysis
uggests that reduced cell membrane cholesterol content is
ot the primary mechanism for statin-induced muscle
Figure 6 Rate of Elevated Liver
Enzymes by Atorvastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduc-
tion in low-density lipoprotein cholesterol (LDL-C) for low-dose (10 mg) and
high-dose (80 mg) atorvastatin.
Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were Reported, and Used for the Present Analysis
Table 2 Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were Reported, and Used for the Present Analysis
Study Arm (Ref. No.) Year Statin Dose* Dose Category n
Follow-Up,
yrs Male, % Age, yrs
Incident
Cancer
% LDL
Reduction
Absolute LDL
Reduction
Achieved
LDL Cancer Site (Primary)
EXCEL (7) 1991 Lovastatin 20 Low 1,642 0.9 59 56 18 24 43 137 NR
EXCEL (7) 1991 Lovastatin 20 BID Intermediate 1,646 0.9 59 56 8 34 61 119 NR
EXCEL (7) 1991 Lovastatin 40 Intermediate 1,645 0.9 59 56 20 30 54 126 NR
EXCEL (7) 1991 Lovastatin 80 High 1,649 0.9 59 56 18 40 72 108 NR
4S (8) 1994 Simvastatin 20–40 Intermediate 2,221 5.4 82 58 90 35 66 122 GI 12
WOSCOPS (9) 1995 Pravastatin 40 Intermediate 3,302 4.9 100 55 116 26 50 142 GU 32, GI 31, respiratory 27,
other 26
CARE (10) 1996 Pravastatin 40 Intermediate 2,081 5 86 59 172 30 41 98 GI 26, breast 14, hematological
8, melanoma 4
AFCAPS/TexCAPS (11) 1998 Lovastatin 20–40 Intermediate 3,304 5.2 85 58 252 24 36 114 Prostate 109, colon 25, lung 22,
melanoma 14, breast 13,
lymphoma 12, bladder 12
LIPID (12) 1998 Pravastatin 40 Intermediate 4,512 6.1 83 62 379 25 38 113 Breast 10, no other sites
reported
ALLHAT-LLT (13) 2002 Pravastatin 40 Intermediate 5,170 4.8 51 66 378 20 25 104 Lung 63, colon 46, breast 34
LIPS (14) 2002 Fluvastatin 80 High 844 3.9 84 60 46 27 35 96 NR
HPS (15) 2002 Simvastatin 40 Intermediate 10,269 5 75 NR† 814 29 39 93 GU 259, GI 228, respiratory 179,
hematological 64, connective
tissue 60, CNS 12
PROSPER (16) 2002 Pravastatin 40 Intermediate 2,888 3.2 48 75 245 34 50 97 GI 65, GU 58, respiratory 46,
breast 18, other 58
*Target dose in milligrams per day, unless otherwise specified. Baseline and achieved LDL-C levels are in mg/dl. Mean follow-up in years is shown. Dose category is in reference to dose effect analysis shown in Figure 10. Primary cancer sites are as reported in the original
publication of the trial. †Mean age not reported in original manuscript, but 48% of patients allocated to simvastatin were 65 years old.
CNS  central nervous system; GI  gastrointestinal; GU  genitourinary; LDL-C  low-density lipoprotein cholesterol; other abbreviations as in Table 1.
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July 31, 2007:409–18 LDL-C Lowering and Risk of Statin Toxicitynjury. Furthermore, based on the assumption that magni-
ude of LDL-C reduction with a statin is a marker for the
egree of HMG-CoA reductase inhibition, the lack of an
ssociation between LDL-C reduction and risk of adverse
vents would suggest non–HMG-CoA reductase-
ependent mechanisms for statin toxicity. Finally, the
resent observation that a higher statin dose is associated
Figure 7 Relationship Between Rates of Newly Diagnosed Canc
The sizes of the open circles represent the relative sizes of the statin treatment a
in each arm). BID  twice daily; LDL-C  low-density lipoprotein-cholesterol; QD 
Figure 8 Relationship Between Rates of Newly Diagnosed Canc
The sizes of the open circles represent the relative sizes of the statin treatment aith increased risk of elevated liver enzymes for any given
eduction in LDL-C is consistent with general clinical
xperience of increased risk of adverse events in settings that
ncrease circulating statin concentrations (26).
DL-C lowering and risk of cancer. Unlike the relation-
hip between magnitude of LDL-C lowering and risk of
bnormal liver enzymes or rhabdomyolysis, we observed a
er 100,000 Person-Years and % LDL-C Reduction
.e., number of patients
daily. See text for trial acronym definitions.
er 100,000 Person-Years and Absolute LDL-C Reduction
.e., number of patients in each arm). Abbreviations as in Figure 7.er p
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LDL-C Lowering and Risk of Statin Toxicity July 31, 2007:409–18isturbing significant inverse relationship between achieved
DL-C levels and risk of newly diagnosed cancer. Several
actors are critical to the proper interpretation of these
ndings, including the recognition that the present obser-
ation is exploratory and hypothesis-generating. In addi-
ion, the current findings do not demonstrate causality
etween low achieved LDL-C levels or statin use and
ancer. However, it is also important to note that the
rimary end point utilized in the large-scale statin trials
emonstrating benefit is typically a combined cardiovascular
Figure 9 Relationship Between Rates of Newly Diagnosed Canc
The sizes of the open circles represent the relative sizes of the statin treatment a
Figure 10 Rate of Newly Diagnosed
Cancer by Statin Dose Category
Rate of newly diagnosed cancer per 100,000 person-years for each 10% reduc-
tion in low-density lipoprotein-cholesterol (LDL-C) for the following statin dose
categories: low dose (lovastatin 20 mg), intermediate dose (lovastatin 40 mg,
simvastatin 40 mg, and pravastatin 40 mg), and high dose (lovastatin 80 mg,
fluvastatin 80 mg).Tnd point and not total mortality. The robust evidence
emonstrating the efficacy of statins in cardiovascular pro-
ection is not undermined by the present analysis, and
emains the basis for current guidelines and clinical practice.
It is also important to differentiate the question posed by
his analysis from the objectives of prior statin-cancer
nalyses. With the exception of the PROSPER (Prospective
tudy of Pravastatin in the Elderly at Risk), in which new
ancer diagnoses were more frequent on pravastatin than on
lacebo (16), all large prospective randomized statin trials
ave shown no difference in the risk of incident cancer in
tatin-treated patients compared with placebo. In the Heart
rotection Study, the largest randomized statin trial with
ore than 10,000 patients allocated to simvastatin, the
ncidence of new cancer diagnoses was similar in the statin
rm compared with the placebo arm (event rate ratio 1.00,
5% confidence interval 0.91 to 1.11) (15).
In meta-analyses of randomized statin trials, The Cho-
esterol Treatment Trialists’ Collaborators and other inves-
igators have shown that statins have a neutral effect on
ncident cancer when compared with placebo in randomized
ontrolled trials (21,27). This body of evidence is reassuring
hat statin use in itself is not associated with an increased
isk of cancer compared with placebo. However, such
eta-analyses do not answer the question addressed by the
resent study: What is the relationship between LDL-C
owering in statin-treated patients and incident cancer? This
uestion is particularly relevant in the present-day era of
lower is better.” The published meta-analyses are limited in
ddressing this question particularly because the 4 random-
zed trials of intensive LDL-C lowering (PROVE-IT–
er 100,000 Person-Years and Achieved LDL-C Level
.e., number of patients in each arm). Abbreviations as in Figure 7.er p
rms (iIMI-22, A to Z, TNT [Treating to New Targets study],
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July 31, 2007:409–18 LDL-C Lowering and Risk of Statin Toxicitynd IDEAL [Incremental Decrease in Endpoints through
ggressive Lipid Lowering study]) were not placebo con-
rolled and hence were not included in the meta-analyses.
The present observation is consistent with many epide-
iologic studies associating low cholesterol levels with
igher incidence of cancer (28). The increase in cancer
eaths in epidemiologic studies appeared to counteract the
ower cardiac mortality associated with lower cholesterol,
esulting in a fairly neutral effect on overall mortality across
holesterol levels (29,30). In most of these studies, the
ncidence of cancer was greater in participants with baseline
otal cholesterol levels of160 mg/dl compared with higher
evels. A comprehensive overview of the epidemiologic data
oncluded that definitive interpretation of the association
etween low cholesterol levels and cancer was not possible
ut was likely explained by confounding (28). One potential
xplanation is the possibility that low cholesterol levels are
imply the effect of the disease rather than the cause, and is
resent before the clinical manifestation of cancer (i.e.,
ccult malignancy causes low cholesterol levels which are
hen associated with cancer when it becomes clinically
anifest). This possibility is inconsistent with the persis-
ence of statistical association between cancer and low
holesterol after excluding early deaths (within 5 years after
tudy baseline) in some of the epidemiologic studies (28).
tudy limitations. The present findings and their implica-
ions should be viewed within the context of several limi-
ations. We used summary data as presented in the pub-
ished manuscript of each trial. A more detailed analysis
sing individual patient data from all the trials may yield
ifferent results. The current analysis relies on rates of
dverse events as reported in the controlled and relatively
estricted environment of randomized clinical trials. Unlike
ommon clinical practice, the controlled setting of a clinical
rial often is characterized by stringent criteria to exclude
ubjects with certain conditions that may increase the risk of
dverse events, along with close follow-up and awareness of
arly laboratory or clinical signs of toxicity. It is conceivable
hat the nature of the relationship between lipid lowering
nd adverse events is altered by these clinical trial charac-
eristics, and that such a relationship may be different when
xamined in a “real-life” clinical environment.
Furthermore, we used adverse event rates as reported and
efined in each study. Our findings are limited by this lack
f standardization, to the extent that these trials vary in their
opulation characteristics and protocols for monitoring and
eporting adverse events. Moreover, given the small number
f cases of rhabdomyolysis across the various statin doses, a
eliable dose effect analysis of rhabdomyolysis rates could
ot be performed. Hence, it is unclear whether the observed
mpact of statin dose on rates of elevated liver enzymes
ould be extrapolated to the risk of rhabdomyolysis. Finally,
t should be emphasized that the association of cancer with
ower achieved LDL-C levels observed in the present
nalysis does not imply causality. Not withstanding the
imitations of the approach, by using the cumulative size ofatient exposure in these trials, the present analysis provides
unique and robust opportunity to examine the clinically
elevant relationship between magnitude of LDL-C lower-
ng and adverse events.
onclusions
he present findings suggest that the risk of statin-
ssociated liver enzyme elevations or muscle injury is not
elated to the magnitude of LDL-C lowering but is more
ikely determined by drug- and dose-specific effects. Fur-
hermore, a concerning inverse relationship between
chieved LDL-C levels in statin-treated patients and risk of
ancer was observed, and requires further investigation.
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